US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Genprex, Inc.

News headline image
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
From Genprex, Inc.
Via GlobeNewswire
Tickers GNPX
News headline image
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Participate in Upcoming Investor Conference in March
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Present in November CEO Roadshow Webinar
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Participate in September Investor Conferences
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Participate in a Monthly CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Participate in Upcoming May Investor Conferences
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Participate in CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
From Genprex, Inc.
Via Business Wire
Tickers GNPX
News headline image
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
From Genprex, Inc.
Via Business Wire
Tickers GNPX